Zhili Zeng1, Zebiao Cao1, Enxin Zhang2,3, Haifu Huang2, Ying Tang4. 1. The First School of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China. 2. Department of Oncology, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong 518000, China. 3. Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China. 4. Department of Oncology, Lingnan Medical Research Center of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510405, China.
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is a malignant tumor with rapid progression, high recurrence rate and poor prognosis. The objective of our investigation was to explore the prognostic value of CDK5R1 in HCC. METHODS: The raw data of HCC raw data were downloaded from The Cancer Genome Atlas (TCGA) database. The Wilcoxon signed-rank test, Kruskal-Wallis test and logistic regression were applied to investigate the relevance between the CDK5R1 expression and clinicopathologic characteristics in HCC. Kaplan-Meier and Cox regression analysis were employed to examine the association between clinicopathologic features and survival. Gene set enrichment analysis (GSEA) was applied to annotate the biological function of CDK5R1. RESULTS: CDK5R1 was highly expressed in HCC tissues. The high expression of CDK5R1 in HCC tissues was significantly associated with tumor status (P=0.00), new tumor event (P=0.00), clinical stage (P=0.00) and topography (P=0.00). Elevated CDK5R1 had significant correlation with worse overall survival (OS; P=7.414e-04), disease-specific survival (DSS; P=5.642e-04), disease-free interval (DFI; P=1.785e-05) and progression-free interval (PFI; P=2.512e-06). Besides, univariate and multivariate Cox regression analysis uncovered that increased CDK5R1 can independently predict adverse OS (P=0.037, hazard ratio [HR]= 1.7 (95% CI [1.0-2.7])), DFI (P=0.007, hazard ratio [HR]= 3.0 (95% CI [1.4-6.7])), PFI (P=0.007, hazard ratio [HR]= 2.8 (95% CI [1.3-5.9])). GSEA disclosed that notch signaling pathway and non-small cell lung cancer were prominently enriched in CDK5R1 high expression phenotype. CONCLUSIONS: Increased CDK5R1 may act as a promising independent prognostic factor of poor survival in HCC.
BACKGROUND: Hepatocellular carcinoma (HCC) is a malignant tumor with rapid progression, high recurrence rate and poor prognosis. The objective of our investigation was to explore the prognostic value of CDK5R1 in HCC. METHODS: The raw data of HCC raw data were downloaded from The Cancer Genome Atlas (TCGA) database. The Wilcoxon signed-rank test, Kruskal-Wallis test and logistic regression were applied to investigate the relevance between the CDK5R1 expression and clinicopathologic characteristics in HCC. Kaplan-Meier and Cox regression analysis were employed to examine the association between clinicopathologic features and survival. Gene set enrichment analysis (GSEA) was applied to annotate the biological function of CDK5R1. RESULTS: CDK5R1 was highly expressed in HCC tissues. The high expression of CDK5R1 in HCC tissues was significantly associated with tumor status (P=0.00), new tumor event (P=0.00), clinical stage (P=0.00) and topography (P=0.00). Elevated CDK5R1 had significant correlation with worse overall survival (OS; P=7.414e-04), disease-specific survival (DSS; P=5.642e-04), disease-free interval (DFI; P=1.785e-05) and progression-free interval (PFI; P=2.512e-06). Besides, univariate and multivariate Cox regression analysis uncovered that increased CDK5R1 can independently predict adverse OS (P=0.037, hazard ratio [HR]= 1.7 (95% CI [1.0-2.7])), DFI (P=0.007, hazard ratio [HR]= 3.0 (95% CI [1.4-6.7])), PFI (P=0.007, hazard ratio [HR]= 2.8 (95% CI [1.3-5.9])). GSEA disclosed that notch signaling pathway and non-small cell lung cancer were prominently enriched in CDK5R1 high expression phenotype. CONCLUSIONS: Increased CDK5R1 may act as a promising independent prognostic factor of poor survival in HCC.
Authors: Sandra M Ehrlich; Johanna Liebl; Maximilian A Ardelt; Thorsten Lehr; Enrico N De Toni; Doris Mayr; Lydia Brandl; Thomas Kirchner; Stefan Zahler; Alexander L Gerbes; Angelika M Vollmar Journal: J Hepatol Date: 2015-02-07 Impact factor: 25.083
Authors: S Erridge; P H Pucher; S R Markar; G Malietzis; T Athanasiou; A Darzi; M H Sodergren; L R Jiao Journal: Br J Surg Date: 2017-06-19 Impact factor: 6.939
Authors: Karine Pozo; Emely Castro-Rivera; Chunfeng Tan; Florian Plattner; Gert Schwach; Veronika Siegl; Douglas Meyer; Ailan Guo; Justin Gundara; Gabriel Mettlach; Edmond Richer; Jonathan A Guevara; Li Ning; Anjali Gupta; Guiyang Hao; Li-Huei Tsai; Xiankai Sun; Pietro Antich; Stanley Sidhu; Bruce G Robinson; Herbert Chen; Fiemu E Nwariaku; Roswitha Pfragner; James A Richardson; James A Bibb Journal: Cancer Cell Date: 2013-10-14 Impact factor: 31.743
Authors: Damian Szklarczyk; John H Morris; Helen Cook; Michael Kuhn; Stefan Wyder; Milan Simonovic; Alberto Santos; Nadezhda T Doncheva; Alexander Roth; Peer Bork; Lars J Jensen; Christian von Mering Journal: Nucleic Acids Res Date: 2016-10-18 Impact factor: 16.971